squamous cell carcinoma of the head and neck
Conditions
Interventions
Test group:68Ga-NOTA-WL12 PET/CT
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Pathologically diagnosed as HNSCC; (2) Immunohistochemical staining confirmed that the PD-L1 expression in the lesion was positive; (3) Capable of making decisions, voluntarily participating in this clinical study, and signing a written informed consent form before the trial implementation; (4) Age 18-75 years old; (5) Expected lifespan over 3 months; (6) No previous treatment received; The surgeon assessed that the tumor could be surgically removed or potentially resectable, and planned to use ruxolitinib combined with taliglucosa for neoadjuvant therapy before the surgery; (7) ECOG score 0-1.
Exclusion criteria
Exclusion criteria: (1) Severe impairment of liver and kidney functions; (2) Severe impairment of coagulation function; (3) Presence of bacterial, fungal or viral infections requiring systemic treatment; (4) Comorbid with other malignant tumors; (5) Pregnant or lactating women; (6) Any other conditions as determined by the researchers to be unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum standardized uptake value;PD-L1 expression;Pathological efficacy evaluation; | — |
Countries
China
Contacts
Public ContactRui Huang
West China Hospital of Sichuan University
Outcome results
None listed